TV50717-CNS-40223: The purpose of this study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life.
Our laboratory takes a geroscience approach to understanding biological processes that contribute to the pathogenesis of Alzheimer’s disease. The long-term goals of our laboratory are to: identify nonpharmacological interventions that target insulin and glutamate signaling pathways that prevent or alleviate cognitive decline and elucidate their mechanisms of action in order to identify pharmacological targets for treating Alzheimer’s disease and related dementias. To address these goals, our laboratory has several ongoing research interests examining the contribution of body temperature
Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
The purpose of this clinical trial is to assess the blood pressure lowering effects of lorundrostat, taken once daily, in patients with high blood pressure.
The purpose of this clinical trial is to assess the blood pressure lowering effects of lorundrostat, taken once daily, in patients with high blood pressure.
The study will test whether the study device, the ProVee Urethral Expander System, can be placed in your urethra safely to treat your urinary symptoms due to your enlarged prostate.
The study is designed to identify the best way to treat pulmonary embolism- with blood thinners alone or blood thinners with catheter directed therapy.
